Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

1 Nov 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Radiomics and Machine Learning in Medical Imaging

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30395155
DOI: 10.1093/annonc/mdy495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicPMID 30395155Read ↗

The status of tumor mutational burden and immunotherapySemantic proximity Read ↗

Tumor Mutation Burden and Cancer Treatment.Semantic proximity Read ↗

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.Semantic proximity Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?Semantic proximity Read ↗

Tumor mutational load predicts survival after immunotherapy across multiple cancer typesSemantic proximity Read ↗

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read ↗

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.Semantic proximity Read ↗

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read ↗

Methods of measurement for tumor mutational burden in tumor tissueSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.